Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lead-in observational study of bleeding events in severe hemophilia A on factor VIII replacement therapy
2019-000447-26Phase 4Terminated
- Sponsor
- Spark Therapeutics
- Start
- Aug 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Factor VIII in hemophilia A, sponsored by Spark Therapeutics. Primary endpoint: Frequency of bleeding events. Started Aug 2019; status: terminated.
02
Drugs
Factor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2019-000447-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000447-26.